PHIBRO ANIMAL HEALTH CORP — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Phibro reported Q1 FY2027 net sales of $386.8M (+6% YoY), net income of $29.5M (+11%), and adjusted EBITDA of $64.3M (+4%), driven by strong Mineral Nutrition (+17% sales) and Performance Products (+16%) growth, while Animal Health grew 3% despite a $5.2M headwind from Brazil virginiamycin regulatory challenges. Management maintained full-year FY2027 guidance: net sales $1.55–1.60B (+4%), adjusted EBITDA $258–268M (+3%), and adjusted net income $140–147M (+9%), assuming no additional Brazil virginiamycin sales for remainder of fiscal year—framing any future approval as upside. The company is also pursuing a $0.6M restructuring charge for planned Chicago Heights manufacturing facility closure and generated $21.7M free cash flow over twelve months ended September 30, 2026.
Why this rating
Solid Q1 with modest topline beat and EPS growth, but guidance held flat signals management conservatism. Mineral/Performance segments strong; core Animal Health flattish. Brazil virginiamycin uncertainty and facility closure are minor headwinds relative to $764M market cap. Routine quarterly disclosure.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.